GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug conjugate in multiple myeloma.
GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid Read More »
